Related Experiment Videos
Empiric therapy of community-acquired pneumonia
1Department of Pulmonary & Critical Care Medicine and Clinical Medicine, Louisiana State University Health Sciences Center at Shreveport, 71130, USA.
Abstract:
Community-acquired pneumonia (CAP) remains a common and serious clinical problem despite the availability of potent antibiotics and aggressive supportive measures. The management of CAP begins with recognition of the likely pathogens causing the illness in the individual patient; identification of several simple clinical clues allows the organization of the broad variety of possible organisms into a more manageable list of likely pathogens. Once the most likely pathogens are identified, then initial antibiotics may be chosen to cover those possibilities. A number of treatment guidelines have been introduced in the past 10 years, most of which share more similarities than differences. We review 2 of the more established guidelines, those published by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA). We also review the likely modifications of the ATS guidelines and discuss the impact of bacterial resistance on antibiotic choices.
Insights
Community-acquired pneumonia (CAP) is a serious illness. This review covers likely pathogens, treatment guidelines from the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA), and the impact of antibiotic resistance on CAP management.
Area of Science:
- Infectious Diseases
- Pulmonology
- Clinical Microbiology
Background:
- Community-acquired pneumonia (CAP) presents a significant clinical challenge.
- Effective management hinges on identifying causative pathogens and appropriate antibiotic selection.
- Despite advances, bacterial resistance impacts treatment efficacy.
Purpose of the Study:
- To review established clinical guidelines for CAP management.
- To discuss potential modifications to existing guidelines.
- To analyze the influence of antimicrobial resistance on antibiotic choices for CAP.
Main Methods:
- Review of established treatment guidelines, specifically from the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA).
- Analysis of clinical clues for pathogen identification.
- Discussion of bacterial resistance patterns and their impact on empirical antibiotic therapy.
Main Results:
- Clinical clues aid in narrowing the spectrum of likely pathogens.
- Established guidelines offer a framework for initial antibiotic selection.
- Bacterial resistance necessitates careful consideration in antibiotic choice.
Conclusions:
- Accurate pathogen identification is crucial for effective CAP treatment.
- Adherence to guidelines, with consideration for local resistance patterns, optimizes patient outcomes.
- Ongoing evaluation of resistance trends is vital for updating CAP management strategies.